Dr. Ardeshir Ghavamzadeh

Dr. Ardeshir Ghavamzadeh |Clyto Access

Tehran University of Medical Sciences

Keynote Speaker

Expertise: Bone Marrow and Stem Cell Transplantation

Biography:

Dr. Ardeshir  Ghavamzadeh, the distinguished professor, serves as a faculty member at Tehran University of Medical Sciences. He is also the president of the Iranian Society of Medical Oncology and Hematology (ISMOH). He is also the Chief of Oncology-Hematology & BMT at Shariati Hospital in Tehran, where he began his work in stem cell transplantation in 1980 and remains its director today. Ghavamzadeh oversees an active center that transplanted 377 patients in 2010. His team also educates transplantation teams at other centers in Tehran. In 2009, his program began an unrelated stem cell banking project and is actively engaged in cord blood banking.
,

Presentation:

Title: Twenty-six Years of Experience on Stem Cell Transplantation In Iran

Abstract:

Aim: From March 1991 to Oct., 21, 2016, a total of 5777 of hematopoietic stem cell transplantations (HSCTs) were performed in the Hematology-Oncology and Stem Cell Transplantation Research Center, affiliated to Tehran University of Medical Sciences. Here, we report 26 years of experience in HSCT.

Method: In total, 5777 patients underwent HSCT. Of whom, 3858 received allogeneic stem cell transplantation, 1764 autologous stem cell transplantation, and 19 syngeneicstem cell transplantation. The sources of graft were peripheral blood (n=4871), bone marrow (n=549), bone marrow+ peripheral blood (n=19) and cord blood (n=67). Ninety-nine patients received mesenchymal stem cell co-transplantation with HSCT. It is important to point out that the sources of graft for allogeneic HSCT (n=88) were available in our cord blood and stem cell donor program banks.

Result: Stem cell transplantation was performed in patients with Leukemia (n=2499), Inherited Abnormality of Red Blood Cell (n=948), Plasma Cell Disorder (n=794), Lymphoma (n=733), Severe Aplastic Anemia (n=284), Solid Tumors (n=116), Myelodysplastic(MDS)/Myeloproliferative(MPS) Diseases (n=99), Disorders of Immune System (n=98), Inherited Disorder of metabolism (n=55), Histiocytic Disorder (n=10) and Auto-Immune Disease (n=5). Moreover, we used cell-based therapies (n=239) for Post-myocardial Infarction, Multiple Sclerosis, Cirrhosis, Head of Femur Necrosis, Diabetes Mellitus and GvHD treatment. One hundred and thirty-nine autologous transplants have been performed in our institutional outpatient setting. Patients underwent allogeneic transplantation from HLA- matchedidentical siblings (n=3291), HLA mismatched [sibling/other relatives](n=257), syngeneic twins (n=19), HLA matched other relatives (n=257) and  unrelated donors (n=153). About 4230 remained alive between 1 to 308 months after HSCT. The main causes of death were relapse, infections, hemorrhagic cystitis and graft versus host disease.

Conclusion: In Iran, HSCT has been successfully adapted in routine clinical care. Recently, new methods such as double cord blood, haploidentical, unrelated and mesenchymal stem cell transplantation have been used.
,

Related Conferences :

Global Forum on Transplantation Research and Technologies